FDA Drug · D-0490-2021

AcetaZOLAMIDE Tablets, USP 125 mg 100 Tablets Rx only NDC 23155-287-01 Manufactured for: Heritage Pharmaceuticals Inc. Eatontown, NJ 07724

Class II · Terminated

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Affected lots / codes — check yours against thisM200833

Recalling firm: Cardinal Health Inc., Dublin, OH
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 122 bottles
Distribution: FL, GA, SC
Recall initiated: March 15, 2021
Classified: May 24, 2021
Terminated: June 17, 2024
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0490-2021%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →